Page 131 - Read Online

Umar et al. Hepatoma Res 2018;4:71 I http://dx.doi.org/10.20517/2394-5079.2018.31 Page 7 of 7

REFERENCES
1. Gower E, Estes C, Blach S, Shearer KR, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J
Hepatol 2014;61:45-57.
2. Umar M, Khaar HT, Akhter TS, Aslam F, Ahmad SI, et al. Diagnosis, management and prevention of hepatitis C in Pakistan 2017. J Ayub
Med Coll Abbottabad 2016;28:S839-82.
3. Sadler MD, Agarwal K. Treatment of genotype 3 chronic hepatitis C virus infection. Clin Med Insights Ther 2017;9:1-7.
4. Hill A, Simmons B, Gotham D, Fortunak J. Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C. J Virus
Erad 2016;2:28-31.
5. Leroy V, Angus P, Bronowicki JP, Dore GJ, Hezode C, et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and
advanced liver disease: a randomized phase III study (ALLY-3+). Hepatology 2016;63:1430-1.
6. Gamal N, Gitto S, Andreone P. Efficacy and safety of daclatasvir in hepatitis C: an Overview. J Clin Transl Hepatol 2016;4:336-44.
7. National Assembly Secretariat (34th Session). Available from: http://www.na.gov.pk/uploads/documents/questions/1470057800_189.pdf.
[Last accessed on 30 Oct 2018]
8. Hill A, Cooke G. Hepatitis C can be cured globally, but at what cost? Science 2014;345:141-2.
9. Gilead Sciences Inc. Chronic hepatitis C treatment expansion: generic manufacturing for developing countries. 2015. Available from: http://
www.gilead.com/~/media/Files/pdfs/other/HCVGenericAgreementFactSheet.pdf. [Last accessed on 30 Oct 2018]
10. Welzel TM, Petersen J, Herzer K, Ferenci P, Gschwantler M, et al. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high
sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut 2016;65:1861-70.
11. World Health Organization. Prequalification of medicines by WHO. Available from: http://www.who.int/mediacentre/factsheets/fs278/en/.
[Last accessed on 23 Oct 2018]
12. Hill A, Tahat L, Mohammed MK, Tayyem RF, Khwairakpam G, et al. Bioequivalent pharmacokinetics for generic and originator hepatitis C
direct-acting antivirals. J Virus Erad 2018;4:e37-40
13. Hajarizadeh B. Generic direct acting antiviral treatment: the first step towards elimination of hepatitis C in Iran. Hepat Mon 2017;17:e45788.
14. Salama H, Zekri AR, Medhat E, Zakaria Z, Shousha H, et al. Sofosbuvir plus daclatasvir with fixed versus weight adjusted dose of ribavirin
for treatment of HCV, genotype 4 among Egyptian patients. EC Gastroenterology and Digestive System 2016;1:143-53.
15. Aggarwal R, Chen Q, Goel A, Seguy N, Pendse R, et al. Cost-effectiveness of hepatitisC treatment using generic direct-acting antivirals
available in India. PLoS One 2017;12:e0176503.